Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adoptive TIL Therapy With Low-dose IFN-alpha Plus Anti-PD1 in Metastatic Melanoma

NCT03638375 is registered in ClinicalTrials.gov with Leiden University as lead sponsor.

NCT NCT03638375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03638375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adoptive TIL Therapy With Low-dose IFN-alpha Plus Anti-PD1 in Metastatic Melanoma
Lead sponsor
Leiden University
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2018
Completion date
November 29, 2025
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse drug event, effects of immunotherapy, toxicity, drug